Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS

NCT02587806 is registered in ClinicalTrials.gov with Novo Cellular Medicine Institute LLP as lead sponsor.

NCT NCT02587806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02587806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
Lead sponsor
Novo Cellular Medicine Institute LLP
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 28, 2015
Completion date
February 28, 2017
Enrollment
69 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing-remitting